Allos Therapeutics Inc. (ALTH)

[surf1944]

2:53AM Allos Therapeutics presents data suggesting treatment with FOLOTYN reverses trend of progressive resistance observed in patients with drug-resistant relapsed or refractory peripheral T-Cell Lymphoma (ALTH) 2.01 : Co reports results from a retrospective analysis of data from the co's pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. In patients who received three or more lines of therapy prior to enrolling in PROPEL, response rates decreased from 56% to 30%; median progression-free survival decreased from 213.5 days to 95 days. In patients who received two or more lines of therapy prior to enrolling in PROPEL, response rates decreased from 38% to 29%; median progression-free survival decreased from 144 days to 89.5 days. Following treatment with FOLOTYN, response rates and progression-free survival increased relative to the previous line of therapy: In patients who received three or more prior therapies, response rates increased from 30% to 40%; median progression-free survival increased from 95 days to 134 days. In patients who received two or more prior therapies, response rates increased from 29% to 40%; median progression-free survival increased from 89.5 days to 119 days.